Trial
NCT02244112
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Advanced Non-Central Nervous System (CNS) Malignancies
Intervention
Oprozomib
Why stopped
Why study stopped revised to "A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ009 was halted
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-21